検索結果 - Eric Jonasch

結果の絞り込み
  1. 1
    MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma

    MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma 著者: Elshad Hasanov, Eric Jonasch

    出版事項 2021
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  2. 2
    Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

    Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities 著者: Eric Jonasch, Frank G. Haluska

    出版事項 2001
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  3. 3
    NCCN Evidence Blocks

    NCCN Evidence Blocks 著者: Robert W. Carlson, Eric Jonasch

    出版事項 2016
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Renal cell carcinoma

    Renal cell carcinoma 著者: Eric Jonasch, Jianjun Gao, W. Kimryn Rathmell

    出版事項 2014
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  5. 5
    Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

    Alternate sunitinib schedules in patients with metastatic renal cell carcinoma 著者: Sarathi Kalra, Brian I. Rini, Eric Jonasch

    出版事項 2015
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  6. 6
    DDX3 regulates DNA damage-induced apoptosis and p53 stabilization

    DDX3 regulates DNA damage-induced apoptosis and p53 stabilization 著者: Mianen Sun, Tong Zhou, Eric Jonasch, Richard S. Jope

    出版事項 2013
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    Clear cell renal cell carcinoma ontogeny and mechanisms of lethality

    Clear cell renal cell carcinoma ontogeny and mechanisms of lethality 著者: Eric Jonasch, Cheryl L. Walker, W. Kimryn Rathmell

    出版事項 2020
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  8. 8
    Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma

    Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma 著者: Jonathan Verma, Eric Jonasch, Pamela Allen, Nizar Tannir, Anita Mahajan

    出版事項 2011
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  9. 9
    The glycoprotein CD147 defines miRNA‐enriched extracellular vesicles that derive from cancer cells

    The glycoprotein CD147 defines miRNA‐enriched extracellular vesicles that derive from cancer cells 著者: Song Yi Ko, WonJae Lee, Melanie Weigert, Eric Jonasch, Ernst Lengyel, Honami Naora

    出版事項 2023
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib

    Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib 著者: Zita Dubauskas, Joy H. Kunishige, Víctor G. Prieto, Eric Jonasch, Patrick Hwu, Nizar M. Tannir

    出版事項 2009
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules

    Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules 著者: Bradley J. Atkinson, Sarathi Kalra, Xuemei Wang, Tharakeswara Bathala, Paul G. Corn, Nizar M. Tannir, Eric Jonasch

    出版事項 2013
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  12. 12
    The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma

    The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma 著者: Jonathan Verma, Eric Jonasch, Pamela K. Allen, Jeffrey S. Weinberg, Nizar M. Tannir, Eric L. Chang, Anita Mahajan

    出版事項 2012
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events 著者: Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    出版事項 2020
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  14. 14
    Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma

    Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma 著者: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, Surena F. Matin, Pheroze Tamboli, Eric Jonasch, Christopher G. Wood

    出版事項 2010
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  15. 15
    An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays

    An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays 著者: Huifang Guo, Wenbin Liu, Zhenlin Ju, Pheroze Tamboli, Eric Jonasch, Gordon B. Mills, Yiling Lu, Bryan T. Hennessy, Dimitra Tsavachidou

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  16. 16
    Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL

    Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL 著者: Elshad Hasanov, G Chen, Pratim Chowdhury, Justin Weldon, Zhiyong Ding, Eric Jonasch, Subrata Sen, Cheryl L. Walker, Ruhee Dere

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  17. 17
    Site-specific activation of AKT protects cells from death induced by glucose deprivation

    Site-specific activation of AKT protects cells from death induced by glucose deprivation 著者: Meng Gao, Jingdan Liang, Yongling Lu, Huifang Guo, Polina German, Shanshan Bai, Eric Jonasch, Xingsheng Yang, G B Mills, Zhiyong Ding

    出版事項 2013
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  18. 18
    Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell Carcinoma

    Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell Carcinoma 著者: Kathrin Milbury, Amy Spelman, Christopher Wood, Surena F. Matin, Nizar M. Tannir, Eric Jonasch, Louis L. Pisters, Qi Wei, Lorenzo Cohen

    出版事項 2014
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  19. 19
    Mammalian target of rapamycin (<scp>mTOR</scp>) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

    Mammalian target of rapamycin (<scp>mTOR</scp>) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes 著者: Bradley J. Atkinson, Diana H. Cauley, Chaan S. Ng, Randall E. Millikan, Lianchun Xiao, Paul G. Corn, Eric Jonasch, Nizar M. Tannir

    出版事項 2013
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  20. 20
    Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake

    Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake 著者: Song Yi Ko, Won‐Jae Lee, Hilary A. Kenny, Long H. Dang, Lee M. Ellis, Eric Jonasch, Ernst Lengyel, Honami Naora

    出版事項 2019
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: